Sunday, December 09, 2012
Quality of life among breast cancer patients with lymphedema: a systematic review of patient-reported outcome instruments and outcomes.
Tuesday, September 11, 2012
Management of lymphedema.
Management of lymphedema.
Source
Abstract
Wednesday, August 29, 2012
IMPORTANT NOTICE WHICH MAY CHANGE YOUR ACCESS TO LYMPHEDEMA SERVICES IN 2014
WE HAVE ONLY UNTIL SEPT 4, 2012, TO RESPOND TO THIS!! It is up to us to have our voices heard VERY loudly on this.
Medicare Part B
CLAIMS-BASED DATA COLLECTION STRATEGY FOR THERAPY SERVICES PROPOSED
CMS issued proposed rule, CMS1590P, on July 6 that includes a proposal to collect data on patient function related to physical and occupational therapy, and speech language pathology services. Section 3005(g) of the Middle Class Tax Relief and Jobs Creation Act (MCTRJCA) requires CMS to implement, beginning on January 1, 2013, ". . . a claims based data collection strategy that is designed
to assist in reforming the Medicare payment system for outpatient therapy services subject to the limitations of section 1833(g) of the Act.
Such strategy shall be designed to provide for the collection of data on patient function during the course of therapy services in order to better understand patient condition and outcomes."
The proposed appeared in the July 30, 2012 Federal Register. CMS will accept comments on the proposed rule until September 04, 2012, and will respond to them in a final rule with comment period to be issued by November 1, 2012.
The Problem:
1. New non-payable data collection codes for reporting functional limitations for each claim;
2. Goal is new therapist reimbursement based on improvement of function and complexity of services;
3. Proposed criteria for evaluating improvement of functional limitations are all physical measures There are no measures proposed that would measure
lymphedema severity or improvement of lymphatic function;
Action:
Write a letter to CMS pointing out the impact the new rule will have to you, as a lymphedema patient, if there are no quality measures appropriate to describe the severity/complexity of the “functional limitation†of lymphedema, and
therefore neither the severity/complexity of the functional limitation, nor the progress attained by the therapist. This lack of means of describing and
evaluating the improvement achieved by lymphedema therapy could result in the
incorrect conclusion that the therapy is of no medical value and disapproved.
To be assured consideration, comments must be received at one of the addresses provided below, no later than 5 p.m. on September 4, 2012.
ADDRESSES: In commenting, please refer to file code CMS–1590–P. Because of staff and resource limitations, we cannot accept comments by facsimile (FAX) transmission. You may submit comments in one of four ways (please choose only
one of the ways listed):
1. Electronically. You may submit electronic comments on this regulation to regulations
http://www.regulations.gov. Follow the instructions for ``submitting a comment.''
2. By regular mail. You may mail written comments to the following address ONLY:
Centers for Medicare & Medicaid Services, Department of Health and Human
Services, Attention: CMS–1590–P, P.O. Box 8013, Baltimore, MD 21244–8013.
Please allow sufficient time for mailed comments to be received before the close
of the comment period.
3. By express or overnight mail. You may send written comments to the following address ONLY: Centers for Medicare & Medicaid Services, Department of Health and Human Services, Attention: CMS–1590–P, Mail Stop C4–26–05, 7500 Security Boulevard, Baltimore, MD 21244–1850.
4. By hand or courier. If you prefer, you may deliver (by hand or courier) your written comments before the close of the comment period to either of the
following addresses:
a. For delivery in Washington, DC— Centers for Medicare & Medicaid Services,
Department of Health and Human Services, Room 445–G, Hubert H. Humphrey
Building, 200 Independence Avenue SW., Washington, DC 20201. (Because access to
the interior of the Hubert H. Humphrey Building is not readily available to persons without Federal government identification, commenters are encouraged to leave their comments in the CMS drop slots located in the main lobby of the building. A stamp-in clock is available for persons wishing to retain a proof of filing by stamping in and retaining an extra copy of the comments being filed.)
b. For delivery in Baltimore, MD— Centers for Medicare & Medicaid Services,
Department of Health and Human Services, 7500 Security Boulevard, Baltimore, MD
21244–1850. If you intend to deliver your comments to the Baltimore address, please call telephone number (410) 786– 7195 in advance to schedule your arrival with one of our staff members. Comments mailed to the addresses indicated as appropriate for hand or courier delivery may be delayed and received after the comment period.
Robert Weiss, M.S.
Lymphedema Patient Advocate
National Lymphedema Network
Tuesday, November 04, 2008
Supplemental surgical treatment to end stage (stage IV-V) of chronic lymphedema.
Normally, I don't post articles suggesting surgeries on lymphedema. Due to the complications that have been experienced by lymphedema patients, I am strongly opposed to what we call a debulking surgery.
However, this study is interesting for a couple reason. The surgery appears to be one I have never heard of - Auchincloss-Homan's procedure and references to stages IV-V which they call "end-Stage" lymphedema.
I research those items to see what I can find and of course will post the info.
In the meantime, here is the abstract.
Supplemental surgical treatment to end stage (stage IV-V) of chronic lymphedema.
Int Angiol. 2008 Oct
Lee BB, Kim YW, Kim DI, Hwang JH, Laredo J, Neville R.
Department of Surgery, Georgetown University, Washington DC, USA.
AIM: When the lymphedema reaches to its end stages, the complex decongestive therapy (CDT) and/or compression therapy become less effective and increased risk of systemic/general sepsis to become potentially life threatening condition.
METHODS: To improve its clinical management, excisional surgery was performed on 22 patients for their 33 limbs in the end stage of lymphedema as a supplemental therapy, and its efficacy was retrospectively analyzed. Diagnosis was made by radionuclide lymphoscintigraphy and basic laboratory studies (e.g. ultrasonography, magnetic resonance imaging). Twenty-two patients (mean age: 46 years; 3 male and 19 female; 5 primary and 17 secondary) submitted to the excisional surgery on 33 limbs (unilateral: 11; bilateral: 22). Surgery was indicated by further progression of the disease with recurrent sepsis despite adequate antibiotics therapy. A modified Auchincloss-Homan's operation was used to excise grotesquely disfigured soft tissue with advanced dermato-lipo-fibrosclerotic change. The normal limb contour was re-established to allow proper postoperative therapy. Postoperative CDT and compression therapy were mandatorily implemented in all cases.
RESULTS: A postoperative assessment of the treatment results, at 12 months showed an overall improvement in 28 of the 33 limbs: substantial improvement on the condition of limb function and quality of life (QOL), and local and/or systemic sepsis. Eighteen patients with good compliance to maintain the postoperative CDT showed much improved clinical results and QOL through the first interim assessment (24 months).
CONCLUSION: Excisional surgery at the end stage of lymphedema seems to provide substantial improvement of clinical condition and QOL only when mandated postoperative CDT/compression therapy is well kept.
PMID: 18974701 [PubMed - in process]
Sunday, February 11, 2007
Lymphedema - Just Live With It

